Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1
- Sponsor
- Lady Davis Institute
- Study ID
- NCT06373263
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Plain-language summary — OTHERParticipants will receive information about a research study via a plain-language summary. The comparator will be a plain-language summary, since plain-language summaries are commonly used and more easily developed than other tools. The summary will be designed based on Canadian government and other key recommendations, including from the Cochrane Collaboration. It will include Background and Objectives, Methods, Results, Limitations, and Key Message for Patients sections and include information on how evidence informs knowledge or health care options. Abstract will be \< 500 words long and use short, positive, active-voice sentence structures and everyday words. Reading level will be between 8th and 9th grade based on Flesch-Kincaid Grade Level and readability score between 60 and 70 based on Flesch Reading Ease.
- Dissemination Tool (Infographic) — OTHERThe infographic will be developed based on key principles including clearly defining the audience and purpose; sharing a story, rather than just facts, with brief, clear messaging; highlighting main ideas; using an attractive title and images; and following principles of good graphic design.
Study Details
Sharing research results with patients is required by ethical regulations. Yet, most researchers do not share results from their studies with patients. The investigators plan to conduct a series of randomized controlled trials among people with scleroderma, a rare autoimmune disease, in a large international cohort, to identify the most effective methods for communicating study results with patients. The first trial in the series will compare a research dissemination tool (infographic) against a plain-language summary comparator. Participants will be randomly assigned to receive the dissemination tool or comparator. Study participants will rate communication tools for (1) information completeness; (2) understandability; and (3) ease of use of format. Our results can be used by researchers and patient organizations who disseminate research results so that they can tailor the way they disseminate results to patient needs.
Key Dates
- Start date
- Dec 5, 2025
- Status verified
- Dec 2025
- Primary completion
- Dec 19, 2025
- Completion
- Jan 2, 2026
Study Design
- Enrollment
- 128 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Experimental: Dissemination tool (infographic)Infographic
- Active Comparator: Plain-language summaryPlain-language summary
Primary Outcome Measure
Completeness [ Time Frame: Immediately Post-intervention (intervention and outcomes in one login - outcomes approx 30 min after randomization) ]
Central Contacts
- Brett D Thombs, PhD514-340-8222
- Marie-Eve Carrier, MSc514-265-8676
Related Studies
- Scleroderma Registry & Repository at the Hospital for Special SurgeryRecruiting · Hospital for Special Surgery, New York · New York, New York
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruiting · Sanford Health · Sioux Falls, South Dakota
- New Orleans Pulmonary Hypertension BiobankRecruiting · Louisiana State University Health Sciences Center in New Orleans · New Orleans, Louisiana
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruiting · Duke University · Durham, North Carolina